Subconjunctival dexamethasone implant for non-necrotizing scleritis

In all patients, symptoms disappeared before day 7, and most of them were symptoms-free on day 2. The implant was visible at least up to day 45. One recurrence was noted in the 6-month follow-up in a patient with rheumatoid arthritis and non-necrotizing diffuse scleritis and was treated with oral steroids. No patient developed ocular hypertension or any kind of complications during the follow-up period, except for subconjunctival hemorrhage.Dexamethasone implant was safely and effectively used as a local therapy for non-necrotizing scleritis.